290 related articles for article (PubMed ID: 24443384)
1. The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system.
Solomon DH; Patrick AR; Schousboe J; Losina E
J Bone Miner Res; 2014 Jul; 29(7):1667-74. PubMed ID: 24443384
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
[TBL] [Abstract][Full Text] [Related]
3. A 3i hip fracture liaison service with nurse and physician co-management is cost-effective when implemented as a standard clinical program.
Beaupre LA; Lier D; Smith C; Evens L; Hanson HM; Juby AG; Kivi P; Majumdar SR;
Arch Osteoporos; 2020 Jul; 15(1):113. PubMed ID: 32699946
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of fracture liaison services: a Markov model using Dutch real-world data.
Li N; van den Bergh JP; Boonen A; Wyers CE; Bours SPG; Hiligsmann M
Osteoporos Int; 2024 Feb; 35(2):293-307. PubMed ID: 37783759
[TBL] [Abstract][Full Text] [Related]
5. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of a fracture liaison service--a real-world evaluation after 6 years of service provision.
Yong JH; Masucci L; Hoch JS; Sujic R; Beaton D
Osteoporos Int; 2016 Jan; 27(1):231-40. PubMed ID: 26275439
[TBL] [Abstract][Full Text] [Related]
7. A model-based cost-effectiveness analysis of fracture liaison services in China.
Li N; Si L; Boonen A; van den Bergh JP; Hiligsmann M
Arch Osteoporos; 2022 Oct; 17(1):132. PubMed ID: 36195760
[TBL] [Abstract][Full Text] [Related]
8. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
9. Economic impact and cost-effectiveness of fracture liaison services: a systematic review of the literature.
Wu CH; Kao IJ; Hung WC; Lin SC; Liu HC; Hsieh MH; Bagga S; Achra M; Cheng TT; Yang RS
Osteoporos Int; 2018 Jun; 29(6):1227-1242. PubMed ID: 29460102
[TBL] [Abstract][Full Text] [Related]
10. Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service.
Yates CJ; Chauchard MA; Liew D; Bucknill A; Wark JD
J Clin Densitom; 2015; 18(2):150-6. PubMed ID: 25797867
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.
Moriwaki K; Noto S
Osteoporos Int; 2017 Feb; 28(2):621-632. PubMed ID: 27699441
[TBL] [Abstract][Full Text] [Related]
12. Patient Healthcare Trajectory and its Impact on the Cost-Effectiveness of Fracture Liaison Services.
Senay A; Fernandes JC; Delisle J; Morin SN; Dragomir A; Nazha S; Perreault S
J Bone Miner Res; 2021 Mar; 36(3):459-468. PubMed ID: 33484586
[TBL] [Abstract][Full Text] [Related]
13. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision.
McLellan AR; Wolowacz SE; Zimovetz EA; Beard SM; Lock S; McCrink L; Adekunle F; Roberts D
Osteoporos Int; 2011 Jul; 22(7):2083-98. PubMed ID: 21607809
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study.
Leal J; Gray AM; Hawley S; Prieto-Alhambra D; Delmestri A; Arden NK; Cooper C; Javaid MK; Judge A;
J Bone Miner Res; 2017 Feb; 32(2):203-211. PubMed ID: 27632945
[TBL] [Abstract][Full Text] [Related]
15. Real-world cost-effectiveness analysis of the fracture liaison services model of care for hip fracture in Taiwan.
Chien LN; Li YF; Yang RS; Yang TH; Chen YH; Huang WJ; Tsai HY; Li CY; Chan DC
J Formos Med Assoc; 2022 Jan; 121(1 Pt 2):425-433. PubMed ID: 34144861
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
18. Cost-effective osteoporosis treatment thresholds: the United States perspective.
Tosteson AN; Melton LJ; Dawson-Hughes B; Baim S; Favus MJ; Khosla S; Lindsay RL;
Osteoporos Int; 2008 Apr; 19(4):437-47. PubMed ID: 18292976
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Fracture Liaison Services Compared with Standard of Care in the Secondary Prevention of Fragility Fractures in Spain.
Naranjo A; Prieto-Alhambra D; Sánchez-Martín J; Pérez-Mitru A; Brosa M
Clinicoecon Outcomes Res; 2022; 14():249-264. PubMed ID: 35492806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
